Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24254608 | 0.78 | ADRA2A (0.37) | AREGFRALDH1A1GAAMAPT | |
| SCHEMBL4475523 | 0.75 | ALDH1A1 (0.35) | AREGFRALDH1A1GAAMAPT | |
| SCHEMBL30017647 | 0.75 | ALDH1A1 (0.35) | AREGFRALDH1A1GAAMAPT | |
| SCHEMBL4481502 | 0.75 | ALDH1A1 (0.50) | AREGFRALDH1A1GAAMAPT | |
| SCHEMBL30412014 | 0.72 | AR (0.39) | AREGFRALDH1A1GAAMAPT | |
| SCHEMBL17491410 | 0.71 | S1PR1 (0.37) | ARS1PR1ALDH1A1MAPTADRB1 | |
| SCHEMBL17027005 | 0.71 | AR (0.32) | AR | |
| SCHEMBL3118100 | 0.70 | MAPT (0.57) | AREGFRALDH1A1GAAMAPT | |
| SCHEMBL1191144 | 0.69 | EGFR (0.40) | AREGFRALDH1A1GAAMAPT | |
| SCHEMBL29620781 | 0.68 | ALDH1A1 (0.35) | AREGFRALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982670-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160052897-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-25 | — | — | US | disclosed |
| EP-2982670-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052897-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | AR 3655/4885EGFR 4863/4885S1PR1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.